Benzinga··Bamboo WorksInnoCare Pharma Hits Profitability Milestone Ahead of Schedule
InnoCare Pharma achieved 644 million yuan profit in 2025, two years ahead of schedule, driven by product sales and licensing partnerships. Hong Kong-listed shares trade at modest 14x P/S ratio.
ZBIOautoimmune diseasesglobal expansion